Background: Liraglutide 3 mg was approved by the FDA as an antiobesity drug. A recent study reported that short-term treatment with Liraglutide (20.0 ± 6.4 days) reduces body weight.
Case Presentation: A 35-year-old male not having any medical illness was presented for medical weight-loss management. He was taking Liraglutide (Saxenda) by SC solution multidose pen 0.6 mg in the first week, 1.2 mg in the second week, 1.8 mg in the third week, 2.4 mg in the fourth week, and 3.0 mg in the fifth week, i.e. 0.6-mg dose increase per week. During the treatment period, he was maintained on low-calorie diet, which was not exceeded 1,500 calories/day. During the treatment period, he was on the mild exercise of walking 45 min three times per week. His initial anthropometric measurements include a weight of 118 kg, height 171 cm, and body mass index 40.4.
Conclusion: Short-term (05 weeks) monotherapy with Liraglutide with restricted-calorie diet and mild exercise significantly reduces the weight by 13.55%.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559087 | PMC |
| http://dx.doi.org/10.4103/jfmpc.jfmpc_213_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.
Diabetol Metab Syndr
December 2024
Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Road, Shanghai, 200127, China.
Aims: To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.
Methods: This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.
Mol Metab
October 2024
Antag Therapeutics Aps, Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark. Electronic address:
Article Synopsis
- Obesity is a serious global health issue, and while GLP-1 receptor agonists help, there's still a need for better treatments, like the new GIPR peptide antagonist AT-7687.
- The study tested AT-7687's effectiveness in non-human primates over 42 days and found it helped maintain weight stability compared to placebo and worked well alongside liraglutide for enhanced weight loss.
- Results showed significant reductions in weight and key metabolic markers without side effects, indicating AT-7687 could be a valuable new option for obesity treatment.
Obesity in Adolescents: A Review.
JAMA
September 2024
Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis.
Importance: Obesity affects approximately 21% of US adolescents and is associated with insulin resistance, hypertension, dyslipidemia, sleep disorders, depression, and musculoskeletal problems. Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood.
Observations: Obesity in adolescents aged 12 to younger than 18 years is commonly defined as a body mass index (BMI) at the 95th or greater age- and sex-adjusted percentile.
Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice.
Exp Clin Endocrinol Diabetes
September 2024
Division of Diabetes and Metabolism, Nihon University School of Medicine, 173-8610, Tokyo, Japan.
Article Synopsis
- - The study investigates the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular health in diabetic mice lacking ApoE, focusing on atherosclerotic lesion development.
- - Diabetic ApoE-deficient mice were treated with either liraglutide, ipragliflozin, or a combination of both, and results showed reduced atherosclerotic lesions in the combo group compared to those untreated.
- - The findings indicate that combining liraglutide and ipragliflozin may effectively prevent atherosclerosis progression in this diabetic mouse model, highlighting potential therapeutic benefits for cardiovascular health in diabetes.*
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Diabetes Care
April 2024
Department of Medicine (General Internal and Preventive Medicine), University of Alabama at Birmingham, Birmingham, AL.
Objective: We evaluated whether adding basal insulin to metformin in adults with early type 2 diabetes mellitus (T2DM) would increase emotional distress relative to other treatments.
Research Design And Methods: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) of adults with T2DM of <10 years' duration, HbA1c 6.8-8.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!